{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=adjuvant+temozolomide+%28TMZ%29&page=3", "query": { "intervention": "adjuvant temozolomide (TMZ)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 88, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=adjuvant+temozolomide+%28TMZ%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=adjuvant+temozolomide+%28TMZ%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T04:34:14.630Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00589875", "title": "Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "High Grade Glioma" ], "interventions": [ { "name": "CAN-2409", "type": "BIOLOGICAL" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Candel Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2007-03", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2024-04-03", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 4, "location_summary": "Duarte, California • Chicago, Illinois • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589875" }, { "nct_id": "NCT00626990", "title": "Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "DNA methylation analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 751, "start_date": "2007-12", "completion_date": "2029-12", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 72, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00626990" }, { "nct_id": "NCT07223034", "title": "A Study of 177Lu-PSMA-617 in People With Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)", "Glioblastoma, IDH-wildtype", "Diffuse Midline Glioma, H3 K27-Altered", "Diffuse Hemispheric Glioma, H3 G34-mutant", "Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "68Ga-PSMA-PET scan/ MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Quality of Life Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-10-27", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223034" }, { "nct_id": "NCT02287428", "title": "Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Personalized NeoAntigen Peptides", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2014-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287428" }, { "nct_id": "NCT03576612", "title": "GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma, Malignant" ], "interventions": [ { "name": "AdV-tk", "type": "BIOLOGICAL" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Candel Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-02-27", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03576612" }, { "nct_id": "NCT01430351", "title": "Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Supratentorial Glioblastoma" ], "interventions": [ { "name": "Mefloquine", "type": "DRUG" }, { "name": "Memantine Hydrochloride", "type": "DRUG" }, { "name": "Metformin Hydrochloride", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2011-09-14", "completion_date": "2025-02-02", "has_results": false, "last_update_posted_date": "2025-05-07", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01430351" }, { "nct_id": "NCT01478321", "title": "Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "hypofractionated radiation therapy", "type": "RADIATION" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2011-12-14", "completion_date": "2018-09-12", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 5, "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Naperville, Illinois + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Naperville", "state": "Illinois" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478321" }, { "nct_id": "NCT07195591", "title": "Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "GammaTile®", "type": "DEVICE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "RADIATION", "DRUG" ], "sponsor": "GT Medical Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 766, "start_date": "2025-12-10", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orlando, Florida + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195591" }, { "nct_id": "NCT00085254", "title": "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2005-04", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2016-02-25", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085254" }, { "nct_id": "NCT00895960", "title": "Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "CNS Disease", "Brain Diseases" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "RT (Radiotherapy)", "type": "RADIATION" }, { "name": "TMZ (Temozolomide)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2009-05-07", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2018-11-08", "last_synced_at": "2026-10-08T04:34:14.630Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00895960" } ] }